|
1
|
Hearle N, Schumacher V, Menko FH,
Olschwang S, Boardman LA, Gille JJ, Keller JJ, Westerman AM, Scott
RJ, Lim W, et al: Frequency and spectrum of cancers in the
Peutz-Jeghers syndrome. Clin Cancer Res. 12:3209–3215. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McKay V, Cairns D, Gokhale D, Mountford R
and Greenhalgh L: First report of somatic mosaicism for mutations
in STK11 in four patients with Peutz-Jeghers syndrome. Fam Cancer.
15:57–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jenne DE, Reomann H, Nezu J, Friedel W,
Loff S, Jeschke R, Müller O, Back W and Zimmer M: Peutz-Jeghers
syndrome is caused by mutations in a novel serine threonine kinase.
Nat Genet. 18:38–43. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hemminki A, Markie D, Tomlinson I,
Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M,
Höglund P, et al: A serine/threonine kinase gene defective in
Peutz-Jeghers syndrome. Nature. 391:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Z, Ellis I, Zauber P, Iwama T,
Marchese C, Talbot I, Xue WH, Yan ZY and Tomlinson I: Allelic
imbalance at the LKB1 (STK11) locus in tumours from patients with
Peutz-Jeghers' syndrome provides evidence for a
hamartoma-(adenoma)-carcinoma sequence. J Pathol. 188:9–13. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Wu B, Mosig RA, Chen Y, Ye F,
Zhang Y, Gong W, Gong L, Huang F, Wang X, et al: STK11 domain XI
mutations: Candidate genetic drivers leading to the development of
dysplastic polyps in Peutz-Jeghers syndrome. Hum Mutat. 35:851–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ylikorkala A, Avizienyte E, Tomlinson IP,
Tiainen M, Roth S, Loukola A, Hemminki A, Johansson M, Sistonen P,
Markie D, et al: Mutations and impaired function of LKB1 in
familial and non-familial Peutz-Jeghers syndrome and a sporadic
testicular cancer. Hum Mol Genet. 8:45–51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao RX and Xu ZX: Targeting the LKB1
tumor suppressor. Curr Drug Targets. 15:32–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boudeau J, Sapkota G and Alessi DR: LKB1,
a protein kinase regulating cell proliferation and polarity. FEBS
Lett. 546:159–165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vaahtomeri K and Mäkelä TP: Molecular
mechanisms of tumor suppression by LKB1. FEBS Lett. 585:944–951.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Korsse SE, Peppelenbosch MP and van Veelen
W: Targeting LKB1 signaling in cancer. Biochim Biophys Acta.
1835:194–210. 2013.PubMed/NCBI
|
|
12
|
Corradetti MN, Inoki K, Bardeesy N,
DePinho RA and Guan KL: Regulation of the TSC pathway by LKB1:
Evidence of a molecular link between tuberous sclerosis complex and
Peutz-Jeghers syndrome. Gene Dev. 18:1533–1538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shaw RJ, Bardeesy N, Manning BD, Lopez L,
Kosmatka M, DePinho RA and Cantley LC: The LKB1 tumor suppressor
negatively regulates mTOR signaling. Cancer Cell. 6:91–99. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou W, Marcus AI and Vertino PM:
Dysregulation of mTOR activity through LKB1 inactivation. Chin J
Cancer. 32:427–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Magnuson B, Ekim B and Fingar DC:
Regulation and function of ribosomal protein S6 kinase (S6K) within
mTOR signalling networks. Biochem J. 441:1–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fenton TR and Gout IT: Functions and
regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell
Biol. 43:47–59. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meyuhas O and Dreazen A: Ribosomal protein
S6 kinase: From TOP mRNAs to cell size. Progress in molecular
biology and translational science. Hershey J: 109–153. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Inoki K, Kim J and Guan K: AMPK and mTOR
in cellular energy homeostasis and drug targets. Annu Rev Pharmacol
Toxicol. 52:381–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shaw RJ: LKB1 and AMP-activated protein
kinase control of mTOR signalling and growth. Acta Physiol (Oxf).
196:65–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei C, Amos CI, Zhang N, Wang X, Rashid A,
Walker CL, Behringer RR and Frazier ML: Suppression of
Peutz-Jeghers polyposis by targeting mammalian target of rapamycin
signaling. Clin Cancer Res. 14:1167–1171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Veelen W, Korsse SE, van de Laar L and
Peppelenbosch MP: The long and winding road to rational treatment
of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene.
30:2289–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boardman LA, Couch FJ, Burgart LJ,
Schwartz D, Berry R, McDonnell SK, Schaid DJ, Hartmann LC,
Schroeder JJ, Stratakis CA and Thibodeau SN: Genetic heterogeneity
in Peutz-Jeghers syndrome. Hum Mutat. 16:23–30. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mehenni H, Resta N, Guanti G, Mota-Vieira
L, Lerner A, Peyman M, Chong KA, Aissa L, Ince A, Cosme A, et al:
Molecular and clinical characteristics in 46 families affected with
peutz-jeghers syndrome. Dig Dis Sci. 52:1924–1933. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boudeau J, Kieloch A, Alessi DR, Stella A,
Guanti G and Resta N: Functional analysis of LKB1/STK11 mutants and
two aberrant isoforms found in Peutz-Jeghers Syndrome patients. Hum
Mutat. 21:1722003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hemminki A, Tomlinson I, Markie D,
Järvinen H, Sistonen P, Björkqvist AM, Knuutila S, Salovaara R,
Bodmer W, Shibata D, et al: Localization of a susceptibility locus
for Peutz-Jeghers syndrome to 19p using comparative genomic
hybridization and targeted linkage analysis. Nat Genet. 15:87–90.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sanchez-Cespedes M: A role for LKB1 gene
in human cancer beyond the Peutz-Jeghers syndrome. Oncogene.
26:7825–7832. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boudeau J, Baas AF, Deak M, Morrice NA,
Kieloch A, Schutkowski M, Prescott AR, Clevers HC and Alessi DR:
MO25alpha/beta interact with STRADalpha/beta enhancing their
ability to bind, activate and localize LKB1 in the cytoplasm. EMBO
J. 22:5102–5114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smith DP, Spicer J, Smith A, Swift S and
Ashworth A: The Mouse Peutz-Jeghers Syndrome gene Lkbl encodes a
nuclear protein kinase. Hum Mol Genet. 8:1479–1485. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baas AF, Boudeau J, Sapkota GP, Smit L,
Medema R, Morrice NA, Alessi DR and Clevers HC: Activation of the
tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD.
EMBO J. 22:3062–3072. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mehenni H, Gehrig C, Nezu J, Oku A,
Shimane M, Rossier C, Guex N, Blouin JL, Scott HS and Antonarakis
SE: Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and
evidence for allelic and locus heterogeneity. Am J Hum Genet.
63:1641–1650. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alessi DR, Sakamoto K and Bayascas JR:
LKB1-dependent signaling pathways. Annu Rev Biochem. 75:137–163.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miyoshi H, Nakau M, Ishikawa T, Seldin MF,
Oshima M and Taketo MM: Gastrointestinal hamartomatous polyposis in
Lkb1 heterozygous knockout mice. Cancer Res. 62:2261–2266.
2002.PubMed/NCBI
|
|
35
|
Mehenni H, Resta N, Park JG, Miyaki M,
Guanti G and Costanza MC: Cancer risks in LKB1 germline mutation
carriers. Gut. 55:984–990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Lier MGF, Westerman AM, Wagner A,
Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ,
Mathus-Vliegen EM and van Leerdam ME: High cancer risk and
increased mortality in patients with Peutz-Jeghers syndrome. Gut.
60:141–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shackelford DB, Vasquez DS, Corbeil J, Wu
S, Leblanc M, Wu CL, Vera DR and Shaw RJ: mTOR and
HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of
Peutz-Jeghers syndrome. Proc Natl Acad Sci USA. 106:pp.
11137–11142. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sanchez-Cespedes M, Parrella P, Esteller
M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky
D: Inactivation of LKB1/STK11 is a common event in adenocarcinomas
of the lung. Cancer Res. 62:3659–3662. 2002.PubMed/NCBI
|
|
39
|
Partanen JI, Nieminen AI, Mäkelä TP and
Klefstrom J: Suppression of oncogenic properties of c-Myc by
LKB1-controlled epithelial organization. Proc Natl Acad Sci USA.
104:pp. 14694–14699. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JH, Koh H, Kim M, Park J, Lee SY, Lee
S and Chung J: JNK pathway mediates apoptotic cell death induced by
tumor suppressor LKB1 in Drosophila. Cell Death Differ.
13:1110–1122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng PY and Berger SL: LKB1 is recruited
to the p21/WAF1 promoter by p53 to mediate transcriptional
activation. Cancer Res. 66:10701–10708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karuman P, Gozani O, Odze RD, Zhou XC, Zhu
H, Shaw R, Brien TP, Bozzuto CD, Ooi D, Cantley LC and Yuan J: The
Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell
death. Mol Cell. 7:1307–1319. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hudson CC, Liu M, Chiang GG, Otterness DM,
Loomis DC, Kaper F, Giaccia AJ and Abraham RT: Regulation of
hypoxia-inducible factor 1alpha expression and function by the
mammalian target of rapamycin. Mol Cell Biol. 22:7004–7014. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jung CH, Jun CB, Ro SH, Kim YM, Otto NM,
Cao J, Kundu M and Kim DH: ULK-Atg13-FIP200 complexes mediate mTOR
signaling to the autophagy machinery. Mol Biol Cell. 20:1992–2003.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moschetta M, Reale A, Marasco C, Vacca A
and Carratu MR: Therapeutic targeting of the mTOR-signalling
pathway in cancer: Benefits and limitations. Br J Pharmacol.
171:3801–3813. 2014. View Article : Google Scholar : PubMed/NCBI
|
